Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Up 9.9%

Arcutis Biotherapeutics is a biopharmaceutical company that specializes in developing and commercializing treatments for skin diseases. The company's lead product candidate is ARQ-101, an investigational topical treatment for atopic dermatitis (AD), a chronic inflammatory skin disease.

On August 25, 2021, Arcutis Biotherapeutics announced that its stock price had increased by 9.9% on the NASDAQ Global Select Market, reaching a closing price of $34.87 per share. This increase in stock price was attributed to positive news regarding the company's ongoing clinical trial for ARQ-101 in patients with AD.

The Phase 2b/3 clinical trial is evaluating the efficacy and safety of ARQ-101 in patients with moderate-to-severe AD. The trial includes a total of 450 patients, who will be randomly assigned to receive either ARQ-101 or a placebo for up to 28 days. Preliminary results from the trial are expected to be presented at an upcoming medical conference in the fourth quarter of 2021.

The positive news regarding the clinical trial and the resulting increase in stock price reflects investor confidence in Arcutis Biotherapeutics' ability to develop and commercialize effective treatments for skin diseases. The company's focus on developing innovative, targeted therapies has the potential to improve the lives of millions of patients who suffer from chronic skin conditions.